1Beckman, JA, Creager, MA. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002; 287: 2570-2581.
2Inzucchi, SilvioE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review JAMA. 2002; 287: 360-372.
3Kirpichnikov, D, McFarlane, SI, Sowers, JR. Metformin: An Update. Annals of Internal Medicine. 2002,137 (1): 25-33.
4Coniff RF, Shapiro JA, Seaton TB, et al. Multicenter, placebo-controlled trial comparing acarbose with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med. 1995; 98: 443-451.
5Marx N, Sukhova G, Murphy C, et al. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol. 1998;153: 17-23.
6O'Keefe, JH. Jr, Miles, JM, Harris, WH. Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clinic Proceedings 1999; 74 (2): 171-180.
7Buse J. Combining insulin and oral agents.Am J Med. 2000; 108 (suppl 6): 23S-32S.
